| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
104,690,000 |
| Market
Cap: |
103.12(B) |
| Last
Volume: |
259,279 |
Avg
Vol: |
765,410 |
| 52
Week Range: |
$692.45 - $993.95 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
S&P SMALLCAP 600 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 150 |
| Guru Rank Value : 6.9 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
168,566 |
236,471 |
279,472 |
438,206 |
| Total Sell Value |
$164,437,486 |
$226,505,895 |
$262,153,799 |
$373,147,368 |
| Total People Sold |
8 |
14 |
16 |
18 |
| Total Sell Transactions |
15 |
42 |
60 |
120 |
| End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Landry Robert E |
EVP Finance CFO |
• – – |
2020-06-22 |
4 |
D |
$626.19 |
$5,252,482 |
D/D |
(8,388) |
24,885 |
|
- |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2020-06-22 |
4 |
OE |
$555.67 |
$4,945,463 |
D/D |
8,900 |
33,273 |
|
- |
|
| Bassler Bonnie L |
Director |
– • – |
2020-06-19 |
4 |
AS |
$630.01 |
$1,612,211 |
D/D |
(2,559) |
643 |
|
-16% |
|
| Bassler Bonnie L |
Director |
– • – |
2020-06-19 |
4 |
OE |
$391.92 |
$1,002,923 |
D/D |
2,559 |
3,202 |
|
- |
|
| Fenimore Christopher R. |
VP Controller |
• – – |
2020-06-16 |
4 |
AS |
$581.40 |
$2,101,215 |
D/D |
(3,556) |
15,277 |
|
-2% |
|
| Fenimore Christopher R. |
VP Controller |
• – – |
2020-06-15 |
4 |
OE |
$30.63 |
$442,742 |
D/D |
9,406 |
18,833 |
|
- |
|
| Fenimore Christopher R. |
VP Controller |
• – – |
2020-06-15 |
4 |
D |
$587.90 |
$2,157,593 |
D/D |
(3,670) |
16,653 |
|
- |
|
| Zoghbi Huda Y |
Director |
– • – |
2020-06-11 |
4 |
AS |
$625.00 |
$1,066,250 |
D/D |
(1,706) |
643 |
|
-3% |
|
| Zoghbi Huda Y |
Director |
– • – |
2020-06-11 |
4 |
OE |
$391.92 |
$668,616 |
D/D |
1,706 |
2,349 |
|
- |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2020-06-11 |
4 |
AS |
$607.50 |
$604,731 |
D/D |
(988) |
24,373 |
|
-3% |
|
| Zoghbi Huda Y |
Director |
– • – |
2020-06-10 |
4 |
AS |
$606.64 |
$1,041,068 |
D/D |
(1,706) |
643 |
|
-6% |
|
| Zoghbi Huda Y |
Director |
– • – |
2020-06-10 |
4 |
OE |
$391.92 |
$668,616 |
D/D |
1,706 |
2,349 |
|
- |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2020-06-10 |
4 |
D |
$610.18 |
$1,532,772 |
D/D |
(2,512) |
25,361 |
|
- |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2020-06-10 |
4 |
OE |
$272.70 |
$954,450 |
D/D |
3,500 |
27,873 |
|
- |
|
| Sanofi-Aventis |
|
• • • |
2020-06-09 |
4 |
S |
$597.48 |
$71,837,410 |
I/I |
(120,234) |
279,766 |
|
5% |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2020-06-09 |
4 |
AS |
$602.38 |
$2,596,792 |
D/D |
(4,271) |
24,373 |
|
-5% |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2020-06-08 |
4 |
D |
$592.40 |
$6,652,342 |
D/D |
(11,229) |
28,644 |
|
- |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2020-06-08 |
4 |
OE |
$272.70 |
$4,226,850 |
D/D |
15,500 |
29,730 |
|
- |
|
| Goldstein Joseph L |
Director |
– • – |
2020-06-08 |
4 |
AS |
$580.65 |
$6,426,362 |
D/D |
(10,838) |
6,643 |
|
-3% |
|
| Goldstein Joseph L |
Director |
– • – |
2020-06-08 |
4 |
OE |
$413.33 |
$4,479,671 |
D/D |
10,838 |
17,481 |
|
- |
|
| Bassler Bonnie L |
Director |
– • – |
2020-06-05 |
4 |
AS |
$600.00 |
$1,535,400 |
D/D |
(2,559) |
643 |
|
0% |
|
| Bassler Bonnie L |
Director |
– • – |
2020-06-05 |
4 |
OE |
$391.92 |
$1,002,923 |
D/D |
2,559 |
3,202 |
|
- |
|
| Ryan Arthur F |
Director |
– • – |
2020-06-01 |
4 |
AS |
$598.58 |
$60,323 |
D/D |
(100) |
28,743 |
|
-2% |
|
| Sing George L |
Director |
– • – |
2020-05-29 |
4 |
S |
$595.00 |
$596,510 |
I/I |
(1,000) |
7,700 |
|
-10% |
|
| Sanofi-Aventis |
|
• • • |
2020-05-29 |
4 |
S |
$509.85 |
$1,223,411,587 |
I/I |
(2,399,552) |
400,000 |
|
-10% |
|
1366 Records found
|
|
Page 28 of 55 |
|
|
4.45 (0.45%) 
